We have a highly experienced management team. All other trademarks or services marks are those of their respective owners. The GHD subjects were treated weekly for 12 months. The submission to EMA is expected to occur in the first half of 2021. Additional analyses that did not exclude outliers showed mixed results. RayaldeeWe have multiple U.S. patent families relating to Rayaldee. Equivalent patents are granted in Europe and Japan and which expire in 2032 and 2034. 8367607 covers OPK88003 and expires in December 2030, without extension. OPKO has also filed a formulation patent on a long acting oxyntomodulin formulation. For example, most implantable devices are subject to the approval process. For these products, we have an obligation to adhere to the FDA's cGMP regulations. There are many potential bases for liability under the False Claims Act. As of December 31, 2020, we had cash and cash equivalents of $72.2 million. Economic conditions have been, and continue to be, volatile. Our exclusive worldwide agreement with Pfizer Inc. is important to our business. As a result, they may not cover or provide adequate payment for our product candidates. We cannot be certain what or how any such government changes may affect our business. We may not obtain non-U.S. regulatory approvals on a timely basis, if at all.